| Price | $1.04 |
| Year Range | $1.01 – $16.32 |
| Market Cap | $3.8M |
| PE Ratio | 0.75 |
| Industry | Biotechnology |
What Is Calidi Biotherapeutics’s AI Stock Analysis?
Calidi Biotherapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Calidi Biotherapeutics’s momentum in near-real time.
Calidi Biotherapeutics (CLDI) has an AltIndex AI Score of 42/100, currently a Hold signal. The AI Score distills Calidi Biotherapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Calidi Biotherapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Calidi Biotherapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving CLDI’s AI Score?
Fundamentals
Net income for the last quarter was $-4.2M. This represents a decrease of 1.27% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of -27.21%, suggesting positive year-over-year growth. Ebitda for the last quarter was $-4.1M. This represents a decrease of 13.19% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of -22.23%, suggesting positive year-over-year growth. The current P/E ratio is 0.75. This may be considered low, potentially indicating undervaluation and a bullish outlook.
See Calidi Biotherapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $1.04. This represents a decrease of 22.96% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 95.91%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $1.06, which is lower than the previous SMA10 of $1.06. This suggests a potential downward trend in price movement. The RSI is 43.1, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
The business outlook among employees at Calidi Biotherapeutics is low (an estimate of only 44% of employees have a positive outlook), a concerning sign. Calidi Biotherapeutics has an estimate of 3,000 visitors to their webpage. The number of visitors is up by 50% in the last couple of months, a bullish trend as this can indicate can increase in customers.
Explore Calidi Biotherapeutics’s job postings, web traffic and app downloads.
Sentiment & social
The sentiment for the stock on various stock forums is very high, a positive sign. Calidi Biotherapeutics has 230 followers on their Twitter page, with no meaningful increase or decrese in the last couple of months.
Track Calidi Biotherapeutics’s market sentiment.
Frequently Asked Questions: Calidi Biotherapeutics AI Stock Analysis
Calidi Biotherapeutics's AltIndex AI Score is 42/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Calidi Biotherapeutics a Hold (42/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Calidi Biotherapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the CLDI AI Score or sign up to read the full thesis.
